286 related articles for article (PubMed ID: 27375787)
1. Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma.
Li J; Liu F; Gupta S; Li C
Theranostics; 2016; 6(9):1393-402. PubMed ID: 27375787
[TBL] [Abstract][Full Text] [Related]
2. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.
Hu X; Xia F; Lee J; Li F; Lu X; Zhuo X; Nie G; Ling D
Adv Sci (Weinh); 2021 Apr; 8(7):2002545. PubMed ID: 33854877
[TBL] [Abstract][Full Text] [Related]
3. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
[TBL] [Abstract][Full Text] [Related]
4. Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.
Zhu L; Mao H; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jul; 14(4):e1793. PubMed ID: 35396932
[TBL] [Abstract][Full Text] [Related]
5. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.
Clawson GA; Abraham T; Pan W; Tang X; Linton SS; McGovern CO; Loc WS; Smith JP; Butler PJ; Kester M; Adair JH; Matters GL
Nucleic Acid Ther; 2017 Feb; 27(1):23-35. PubMed ID: 27754762
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno C; Cassim S; De Leiris N; Durivault J; Faraggi M; Pagès G
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203923
[TBL] [Abstract][Full Text] [Related]
7. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer: Stroma and its current and emerging targeted therapies.
Kota J; Hancock J; Kwon J; Korc M
Cancer Lett; 2017 Apr; 391():38-49. PubMed ID: 28093284
[TBL] [Abstract][Full Text] [Related]
9. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
[TBL] [Abstract][Full Text] [Related]
10. Interventional nanotheranostics in hepatocellular carcinoma.
Chavda VP; Balar PC; Patel SB
Nanotheranostics; 2023; 7(2):128-141. PubMed ID: 36793354
[TBL] [Abstract][Full Text] [Related]
11. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
[TBL] [Abstract][Full Text] [Related]
12. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
[TBL] [Abstract][Full Text] [Related]
13. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
14. Locoregional Therapies and Remodeling of Tumor Microenvironment in Pancreatic Cancer.
De Grandis MC; Ascenti V; Lanza C; Di Paolo G; Galassi B; Ierardi AM; Carrafiello G; Facciorusso A; Ghidini M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628865
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
Loehrer AP; Ferrone CR
Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
Mardin WA; Mees ST
Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.
Dobiasch S; Szanyi S; Kjaev A; Werner J; Strauss A; Weis C; Grenacher L; Kapilov-Buchman K; Israel LL; Lellouche JP; Locatelli E; Franchini MC; Vandooren J; Opdenakker G; Felix K
J Nanobiotechnology; 2016 Dec; 14(1):81. PubMed ID: 27993133
[TBL] [Abstract][Full Text] [Related]
18. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
[TBL] [Abstract][Full Text] [Related]
19. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
Partensky C
Pancreas; 2013 Jul; 42(5):729-39. PubMed ID: 23648843
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?
Tjomsland V; Sandström P; Spångeus A; Messmer D; Emilsson J; Falkmer U; Falkmer S; Magnusson KE; Borch K; Larsson M
BMC Cancer; 2010 Mar; 10():87. PubMed ID: 20214814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
